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Inflammation leads to distinct populations
of extracellular vesicles from microglia
Yiyi Yang1* , Antonio Boza-Serrano1, Christopher J. R. Dunning2, Bettina Hjelm Clausen3,4,
Kate Lykke Lambertsen3,4,5 and Tomas Deierborg1*
Abstract
Background: Activated microglia play an essential role in inflammatory responses elicited in the central nervous
system (CNS). Microglia-derived extracellular vesicles (EVs) are suggested to be involved in propagation of inflammatory
signals and in the modulation of cell-to-cell communication. However, there is a lack of knowledge on the regulation
of EVs and how this in turn facilitates the communication between cells in the brain. Here, we characterized microglial
EVs under inflammatory conditions and investigated the effects of inflammation on the EV size, quantity, and
protein content.
Methods: We have utilized western blot, nanoparticle tracking analysis (NTA), and mass spectrometry to characterize
EVs and examine the alterations of secreted EVs from a microglial cell line (BV2) following lipopolysaccharide (LPS) and
tumor necrosis factor (TNF) inhibitor (etanercept) treatments, or either alone. The inflammatory responses were measured
with multiplex cytokine ELISA and western blot. We also subjected TNF knockout mice to experimental stroke (permanent
middle cerebral artery occlusion) and validated the effect of TNF inhibition on EV release.
Results: Our analysis of EVs originating from activated BV2 microglia revealed a significant increase in the intravesicular
levels of TNF and interleukin (IL)-6. We also observed that the number of EVs released was reduced both in vitro and in
vivo when inflammation was inhibited via the TNF pathway. Finally, via mass spectrometry, we identified 49 unique
proteins in EVs released from LPS-activated microglia compared to control EVs (58 proteins in EVs released from LPS-
activated microglia and 37 from control EVs). According to Gene Ontology (GO) analysis, we found a large increase of
proteins related to translation and transcription in EVs from LPS. Importantly, we showed a distinct profile of proteins
found in EVs released from LPS treated cells compared to control.
Conclusions: We demonstrate altered EV production in BV2 microglial cells and altered cytokine levels and protein
composition carried by EVs in response to LPS challenge. Our findings provide new insights into the potential roles of EVs
that could be related to the pathogenesis in neuroinflammatory diseases.
Keywords: Microglia, Extracellular vesicles (EVs), Neuroinflammation, TNF
Background
Microglia are considered the main innate-immune cells of
the central nervous system (CNS). They continuously sur-
vey their microenvironment and have the ability to interact
with neurons to regulate their activity [1]. In the healthy
brain, microglia continuously survey their surroundings
with highly dynamic processes [2] and become activated in
response to injury, infection or neurodegenerative processes
[3]. Emerging evidence has shown that microglia are key
causative players in neuroinflammation, which in turn is
believed to play a major role in neurodegenerative
diseases [4].
Microglia are highly dynamic cells with the ability to
transform their morphology from ramified to amoeboid
and alter their phenotypes corresponding to diverse con-
ditions. Traditionally, macrophages and microglial cells
are classified into two different phenotypes, M1 and M2.
M1-microglia are proinflammatory, secreting inflamma-
tory cytokines, chemokines, and nitric oxide (NO),
which is believed to result in neuronal dysfunction and
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accelerate the progression of neurodegenerative diseases,
such as Alzheimer’s disease (AD) and Parkinson’s disease
(PD). In contrast, M2-microglia are believed to have
neuroprotective functions, including increased produc-
tion of interleukin (IL)-4 and neurotrophic factors, along
with an increase in phagocytosis which in turn leads to
clearance of cell debris and tissue damage [3, 5]. How-
ever, there is a wide spectrum of microglial activation
between the two defined phenotypes [6], and microglia
might even have specific neuronal functions beyond typ-
ical pro-/anti-inflammatory responses [7]. A better un-
derstanding of the interactions between microglia and
other cells in the brain is therefore needed in order to
design therapies to ameliorate the detrimental effects of
microglial reactions in brain diseases.
The main interaction between cells occur through cel-
lular signaling pathways including autocrine, paracrine,
and endocrine processes [8] and extracellular vesicles
(EVs) can be important to transport signals between
cells. In fact, increasing evidence has shown EVs are
considered one of the main participants in cell-to-cell
communication along with having a proposed role in the
spread of pathology in neurodegenerative disease [9, 10].
These vesicles are able to carry pathogen-associated and
damage-associated molecular patterns that act as signals
to regulate and propagate the inflammatory response
[11–13]. Hence, investigation of EV trafficking under in-
flammatory conditions may broaden our understanding
of the roles of microglia in neurodegenerative diseases,
as well as their potential in therapeutic manipulation.
The secretion of EVs is a highly conserved process
[14]. However, a number of studies using proteomic ana-
lysis of EVs released by various cell types, including
microglia, have revealed a diverse range of markers and
alteration of protein composition [15, 16]. The lack of
knowledge on EV’s regulation in vitro and in vivo halts a
clear understanding of EV functions in cell-to-cell com-
munication. It is likely that different subsets of EVs have
different functional properties, and trafficking of EVs is
most likely modulated by specific signaling pathways.
Although consensus within the field is being reached,
the classification of EVs is not easy. While different sub-
sets of EVs are being described with increasing rate, for
simplicity, we will focus on two different classes of EVs
of different sizes and origins. EVs shed directly from the
plasma membrane are characterized as microvesicles or
ectosomes ranging from 100 to 1000 nm. Exosomes are
generated within the endosomal pathway and terminate
at the multivesicular endosomal body (MVB), whereby
they are released upon the MVB fusing with the plasma
membrane. Generally, the size of exosomes is smaller
than microvesicles and below 100 nm.
A recent study has shown that the size distribution
and protein composition of EVs in macrophages can be
changed after bacterial infection [17]. Thus, there is a
critical need for both identification of specific markers
and particular signaling pathways controlling EV traf-
ficking. The mechanism of action of EVs in microglial
communication is poorly understood. In this study, we
hypothesized that activation of microglia can secrete a
distinct population of EV through modulation of specific
signaling pathways. We investigated the dynamics of EVs
from activated microglial (BV2) cells subjected to lipo-
polysaccharide (LPS) stimulation. We used differential
ultracentrifugation to isolate EVs, including microvesi-
cles and exosomes. EVs were then characterized in terms
of size and concentration by nanoparticle tracking
analysis (NTA), while the origin of EVs was indicated by
western blotting using antibodies against CD63, flotillin-1,
and Alix. Importantly, we also analyzed the levels of in-
flammatory cytokines in EVs. Secretion of EVs was altered
by suppression of inflammation in microglia via inhibition
of tumor necrosis factor (TNF) signaling in vivo and in
vitro. Subsequently, qualitative proteomic analysis was
performed to reveal a different protein composition of
EVs in response to LPS challenge. Taken together, our
findings provide new insights into the role of EVs in regu-
lating microglial cell communication.
Methods
Cell culture
BV2, an immortalized murine microglial cell line, was
cultured in growing medium containing Dulbecco’s
modified Eagle medium (DMEM) (Gibco™GlutaMAX™,
Thermo Fisher Scientific) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (Thermo Fisher Scientific) in 5%
CO2 in air at 37 °C in a humidified incubator. Cells were
re-cultured every 2 days starting at a concentration of
2 × 105 cells/ml in T75 flask (Sarstedt). For a large scale
of EV collection, microglia were plated in T175 flask (Sar-
stedt). For inflammatory activation, cells were challenged
with 1 μg/ml LPS (Sigma-Aldrich, Clony 0127-B8) for 12 h
and then grown for 12 h in serum-free media prior to col-
lection of EVs. For TNF inhibition experiment, microglia
were plated in growing medium either with 1 μg/ml LPS,
200 ng/ml etanercept, or both for 12 h. EVs were collected
from serum-free media 12 h after treatment.
Animals
Adult male C57BL/6 mice (between 7 and 8 weeks of
age, n = 20) were purchased from Taconic Ltd. (Ry,
Denmark) and transferred to the Laboratory of Biomedi-
cine, University of Southern Denmark, where they were
allowed to acclimatize for 7 days prior to surgery. TNF
knockout (TNF-KO) breeding couples were originally
purchased from The Jackson Laboratory and transferred
to the Laboratory of Biomedicine where they were
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established as a colony. Animals were housed under di-
urnal lighting conditions and given free access to food
and water [18]. All animal experiments were performed
in accordance with the relevant guidelines and regula-
tions approved by the Danish Animal Ethical Committee
(numbers 2011/561-1950 and 2013-15-2934-00924).
Induction of experimental stroke, permanent middle
cerebral artery occlusion (pMCAO)
The distal part of the left middle cerebral artery was per-
manently occluded under Hypnorm and Dormicum
anesthesia (fentanyl citrate (0.315 mg/ml; Jansen-Cilag)
and fluanisone (10 mg/ml; Jansen-Cilag, Birkerød,
Denmark), and midazolam (5 mg/ml; Hoffmann- La
Roche, Hvidovre, Denmark)), respectively. After surgery,
mice were injected subcutaneously with 1 ml of 0.9% sa-
line and allowed to recover in a 25 °C controlled envir-
onment. Mice surviving for 5 days were returned to the
conventional animal facility after 24 h. For post-surgical
analgesia, mice were treated with 0.001 mg/20 g bupre-
norphine hydrochloride (Temgesic, Schering-Plough,
Ballerup, Denmark) three times at 8-h intervals, starting
immediately prior to surgery. Mice were allowed to sur-
vive for 1 day (immunofluorescent staining and cytokine
measurement) or 5 days (EV analysis) whereafter they
were killed using either an overdose of pentobarbital
(200 mg/ml) containing lidocaine (20 mg/ml) (Glostrup
Apotek, Glostrup, Denmark) and perfused through the
left ventricle using 4% paraformaldehyde (PFA) or killed
by cervical dislocation. The blood and brains were col-
lected for further analysis.
Extracellular vesicle isolation procedure and transmission
electron microscopy (TEM)
For isolation of EVs, cells were cultivated in growing
medium DMEM and then deprivation of serum for a
period of 12 h. The media was then collected and sub-
jected to a series of low-speed centrifugation steps
(500×g for 10 min, 2000×g for 10 min, and 10,000×g for
30 min) at 4 °C in order to remove cells and cellular
debris. The supernatant was then collected in centrifuge
tubes (Beckman Coulter) and spun at 100,000×g for
70 min before the resultant EV pellet was washed in a
large volume of phosphate-buffered saline (PBS) before
repeating the 100,000×g spin. The pellets containing EVs
were resuspended in 20 μl of PBS and stored at 4 °C or
long term at − 20 °C. For electron microscopic analysis,
samples of EVs were fixed with an equal volume of 2%
PFA and loaded onto Formvar/carbon-coated electron
microscopic grids. EVs were observed under TEM at
80 kV. TEM was carried out at Lund University Bioima-
ging Center.
Measurement of extracellular vesicles size by nanoparticle
tracking analysis (NTA)
The size and total number of EVs were measured by
using NanoSight LM10 (Malvern, UK) with the technol-
ogy of Nanoparticle Tracking Analysis (NTA). In liquid
suspension, particles undergo Brownian motion together
with light scattering properties, the size distribution and
concentration of EVs samples can be obtained [17]. Sam-
ples were diluted with distilled water to obtain optimal
concentration for detection (106–109 particles/ml) and
injected with a continuous syringe system for 30 s × 5
times at speed 50 μl/min. Data acquisition was undertaken
at ambient temperature and measured 5 times by NTA.
Data were analyzed with NTA 2.2 software (Malvern, UK)
with minimum expected particle size 10 nm.
Western blot analysis
Cell pellets and EVs were lysed in RIPA buffer (Sigma-Al-
drich) supplemented with proteinase inhibitors (Thermo
Scientific) and PhosphoStop (Roche Diagnostics GmbH).
The concentration of cell lysates was determined using
bicinchoninic acid assay (BCA) (Thermo Scientific), while
concentrations obtained using NanoSight were utilized to
ensure even loading of EVs. Samples were loaded onto 4–
20% Mini-Protean TGX Precast Gels (Bio-Rad) and then
transferred to Nitrocellulose membranes (Bio-Rad) using
Trans-Blot Turbo System (Bio-Rad). Membranes were
incubated with following primary antibodies: Alix (Cell
Signaling; 1:1000), flotillin-1 (Cell Signaling; 1:1000),
CD63 (Santa Cruz Biotechnology; 1:1000), inducible nitric
oxide synthase (iNOS) (Santa Cruz Biotechnology;
1:3000), NLRP3 (Adipogen; 1:1000) and pro-caspase1
(Adipogen; 1:1000). All secondary antibodies were
horse-radish protein (HRP) conjugated (Vector; 1:5000 or
1:10000). Protein bands were detected using Clarity West-
ern ECL Substrate (Bio-Rad) or Pierce™ ECL Western
Blotting Substrate (ThermoFisher), and imaged on
Bio-Rad ChemiDoc XRS+. Protein levels were normalized
to beta-actin (Sigma-Aldrich; 1:15,000). Image lab™ soft-
ware (Bio-Rad) was used to analyze the results.
Multiplex cytokine enzyme-linked immunosorbent assay
(ELISA)
The concentrations of different cytokines in EVs and in
isolated media as well as serum from mice were mea-
sured with the MSD Mouse Proinflammatory V-Plex
Plus Kit (Interferonγ (IFNγ), IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p70, TNF, C-X-C motif chemokine ligand 1
(KC/GRO), Mesoscale) using a QuickPlex SQ120 Plate
Reader (Mesoscale Discovery, Rockville, USA) according
to the manufacturer’s instructions. The data was ana-
lyzed with MSD Discovery Workbench software. The
levels of cytokines in EVs and media were normalized to
each samples total protein content in cell lysates. In
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total, 6 independent EV samples were analyzed; however,
those samples that were under the lowest detection limit
were removed from the statistical analysis.
Immunohistochemistry
Immunofluorescent double labeling for TNF and CD11b
was performed on 16-μm thick, cryostat-cut tissue sec-
tions from C57BL/6 mice with 1-day survival after
pMCAO as previously described in detail [18, 19].
Extracellular vesicle fluorescent labeling
Following isolation, EVs were labeled with PKH67 Green
Fluorescent Cell Linker Midi Kit for General Cell
Membrane Labeling (Sigma-Aldrich) according to the
manufacturer’s instructions. Briefly, EVs were resus-
pended in 1 ml PBS before 1 ml of Diluent C supple-
mented 4 μl PKH67 dye. Samples were incubated at
room temperature for 4 min prior to the addition of
2 ml of 1% bovine serum albumin (BSA) (VWR Inter-
national) to bind excess dye. Samples were then supple-
mented with 5 ml PBS and placed in 300 kDa Vivaspin
filters (Sartorius Stedim Biotech GmbH, Goettingen,
Germany), prior to centrifugation for 5 min at 4000×g to
remove excess dye. This process was repeated a further
two times, followed by a further two washes in a clean
filter with DMEM (Thermo Fisher Scientific) in place of
PBS. The same procedure minus EVs was carried out as
control.
TNF inhibition on dynamics of extracellular vesicle
trafficking
PKH67-labeled EVs (2 × 1010 particles/ml) were incu-
bated with BV2 cells as indicated previously. After 12 h
incubation, cells were washed three times with PBS and
one time with 1 M NaCl prior to fixation with 4% PFA
for 20 min on ice. Cells were then imaged by fluores-
cence microscope (Olympus IX71) at × 20 magnification
and images processed using Cellsens Standard version
1.6 software (Olympus). Vesicle uptake was analyzed by
measuring fluorescent intensity using ImageJ software
(National Institutes of Health).
Mass spectrometry
Mass spectrometry was carried out on an Orbitrap
Fusion Tribrid MS system (Thermo Scientific) equipped
with a Proxeon Easy-nLC 1000 (Thermo Fisher).
Injected peptides were trapped on an Acclaim PepMap
C18 column (3-μm particle size, 75-μm inner diameter
× 20 mm length). After trapping, gradient elution of pep-
tides was performed on an Acclaim PepMap C18 col-
umn (100 Å 3 μm, 150 mm, 75 μm). The outlet of the
analytical column was coupled directly to the mass spec-
trometer using a Proxeon nanospray source. The mobile
phases for liquid chromatography (LC) separation were
0.1% (v/v) formic acid in LC-mass spectrometry grade
water (solvent A) and 0.1% (v/v) formic acid in aceto-
nitrile (solvent B). Peptides were first loaded with a con-
stant pressure mode with a flow rate of solvent A onto
the trapping column. Subsequently, peptides were eluted
via the analytical column at a constant flow of 300 nl/
min. During the elution step, the percentage of solvent B
increased from 5 to 22% in the first 20 min, then in-
creased to 32% in 5 min and finally to 98% in a further
2 min and was keeping it for 8 min. The peptides were
introduced into the mass spectrometer via a Stainless
steel emitter 40 mm (Thermo Fisher) and a spray volt-
age of 1.9 kV was applied. The capillary temperature was
set at 275 °C.
Data acquisition was carried out using a top N-based
data-dependent method with cycle time of 3 s. The mas-
ter scan was performed in the Orbitrap in the range of
350–1500 mass to charge ratio (m/z) at a resolution of
60,000 full width at half-maximum (FWHM). The filling
time was set at maximum of 50 ms with limitation of
4 × 105 ions. In a second stage of tandem mass spec-
trometry (MS/MS) ion trap collision-induced dissoci-
ation was acquired using parallel mode, filling time
maximum 300 ms with limitation of 2 × 103 ions, a pre-
cursor ion isolation width of 1.6 m/z and resolution of
15,000 FWHM. Normalized collision energy was set to
35%. Only multiply charged (2+ to 5+) precursor ions
were selected for MS/MS. The dynamic exclusion list
was set to 30 s and relative mass window of 5 ppm.
Bioinformatic analysis
Gene Ontology (GO) classifications and enrichments
were performed using FunRich [20]. The identified pro-
teins were compared with web tool Exocarta database
and also with the Top100 exosomal proteins from the
database [21].
Data analysis
MS/MS data were searched with PEAKS (7.5). UniProt
Mus musculus (house mouse, including 16,792 se-
quences) was used with non-tryptic specificity allowing
up to 3 missed cleavages. A 15 ppm precursor tolerance
and a 0.1 Da fragment tolerance were used. Oxidation
(M) and deamidation (NQ) were treated as dynamic
modification and carbamidomethylation (C) as a fixed
modification. Maximum post-translational modification
per peptide was 2. Search results were filtered by using
1% false discovery rate and 2 unique peptides.
The rest was evaluated using either unpaired t test or
one-way ANOVA followed by Tukey’s test for multiple
comparisons. All statistical analysis was done using the
GraphPad Prism 7.0 software for Macintosh (GraphPad
Software, San Diego, CA, USA). Data are presented as
means ± SD. A confidence interval of 95% was set as
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significant. The exact P values are given in the figure
legends. Figures were organized using Adobe Illustrator.
Results
Proinflammatory responses from LPS-stimulated BV2
microglial cells
First, we examined the activation of BV2 cells after 12 h
culture in the presence of 1 μg/ml LPS followed by
deprivation of serum for 12 h to elicit a strong inflam-
matory reaction. The inflammatory enzyme iNOS is
expressed by activated microglia [22] and as expected,
the level of iNOS was significantly increased in cells
upon LPS stimulation (Fig. 1a). Moreover, the protein
levels of other important inflammatory mediators,
NLRP3 (Nod-like receptor protein 3) and pro-caspase1
(involved in the maturation, production, and release of
IL-1β and IL-18 [23]) were found to be elevated
considerably (Fig. 1b, c). According to our previous stud-
ies, the viability of BV2 cells is not affected by LPS acti-
vation [22, 24]. These results suggest that an activated
pro-inflammatory status of microglia remained over the
12 h EV collection period following LPS treatment.
Changes in EV size distribution in response to LPS
activation
Transmission electron microscopy (TEM) was per-
formed to visualize microglial-derived EVs (Fig. 1d). Im-
ages from control condition and LPS treatment revealed
heterogeneous populations of EVs from microglia in the
range between 100 and 1000 nm in diameter. LPS treat-
ment seemed to induce microglial release of larger EVs,
around 200–300 nm in diameter.
To further characterize EVs released under
pro-inflammatory condition by LPS treatment, we com-
pared size distribution of EVs derived from non-activated
and LPS-activated microglia using Nanoparticle Tracking
Analysis (NTA). The range of EVs detected with NTA was
from 50 to 700 nm. Different size subpopulations of EVs
were observed in EVs released from activated and
non-activated microglial cells (Fig. 1f). According to the
diameter of EVs, we can classify them into two subpopula-
tions: one ranging from 50 to 100 nm can be considered
as exosomes and another subpopulation with size
exceeding 100 nm can be regarded as microvesicles
(MVs). As can be seen in Fig. 1f, the population of MVs
ranging from 300 to 400 nm has a higher frequency in the
LPS-activated EVs. We found EVs released from
LPS-activated cells to be significantly larger (178 ±
5.66 nm) compared to the size of EVs from control cul-
tures (159 ± 4.95 nm) (Fig. 1f; p < 0.001). D90 measure-
ment shows the upper limit of 90% measured particles,
and in control condition, the D90 value for EVs was 205 ±
3.61 nm, whereas the value was 254 ± 11.06 nm in
LPS-activated samples (Fig. 1f; p < 0.001). These results
revealed that LPS-stimulated microglia release larger EV
populations compared to control (Fig. 1g). EV samples
were blotted for different EV markers including a marker
for plasma membrane (flotillin-1) and an endosomal
marker (Alix) as well as the EV marker CD63 for MVB
(Fig. 1e) to elucidate the subcellular origin of the EVs [25].
We observed that in EVs released from microglia after
LPS activation had a higher ratio of flotillin-1 and CD63
when compared to those from non-activated cells when
loading equal amounts of EVs in each lane, suggesting al-
tered EV biogenesis and release after an inflammatory
stimulus.
Increased production of TNF and IL-6 in EVs upon LPS
activation
Next, we studied the cytokine release from LPS-activated
BV2 microglia to evaluate the free concentration of re-
leased cytokines and the cytokine concentration in EVs.
Culture medium from activated and non-activated micro-
glia was collected, and EVs were isolated from equal
amounts of medium. EVs, along with the EV-depleted
media, were then subjected to analysis by multiplex
ELISA. Out of ten inflammatory cytokines analyzed, the
levels of two pro-inflammatory cytokines, TNF and IL-6,
were found to be significantly increased in EVs from
activated microglia (Fig. 2a, b). TNF and IL-6 are two
representative pro-inflammatory cytokines produced by
microglia related to neurodegenerative diseases [3].
Notably, there was also a significant upregulation in the
concentration of these two cytokines in medium
(Additional file 1). However, other pro-inflammatory
cytokines such as IL-5 and IL-1β were found to be
increased only in the medium, but not in EVs
(Additional files 1 and 2). Importantly, the level of
TNF was much higher increased, 22-fold, compared
to 5-fold in IL-6. Thus, we further investigated the ef-
fect of TNF in regulation of EV release in the follow-
ing study.
Reduction of EVs by inhibition of inflammation via TNF
pathway
In view of the specific increase of TNF in the EVs after
LPS-stimulation, we set out to further characterize the
role of TNF in the microglial release of EV. To investi-
gate the mechanistic basis for EV regulation on LPS
signaling in microglial cells, we quantified the number of
EVs released from microglia after TNF inhibition with
etanercept upon LPS activation. Notably, activated
microglia secreted a 30-fold increase in the number of
EVs under LPS stimulation (Fig. 3a). In contrast, the
effect of LPS on EV release was completely attenuated
down to control levels using etanercept (200 ng/ml), a
TNF inhibitor that blocks both soluble and transmem-
brane forms of TNF (Fig. 3a). In the presence of the
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TNF inhibitor, the amount of EVs released from cells
was also reduced compared with control condition
(Fig. 3a). Next, we wanted to understand whether the
reduction of EV is caused by decreased EV uptake
through inhibition of TNF. Thus, we assessed the cap-
ability of EV uptake under different conditions as indi-
cated above. We found no significant difference between
the conditions on internalization of PHK76-labeled EVs,
indicating the reduction of EVs was due to TNF treat-
ment on EV release not by affecting EV uptake/turnover
(Additional file 3).
Next, we evaluated the degree of inflammatory status
in microglia in relation to the amount of EVs secreted.
To that aim, the level of iNOS was analyzed by western
blot on cells previously treated in different conditions.
We found two-fold reduction in iNOS levels following
Fig. 1 Characterization of microglia-derived extracellular vesicles. Microglia (BV2) were activated by treatment with LPS for 12 h before
extracellular vesicles were isolated from the media of both LPS-treated (LPS) or control (CTRL) cells. a Western blot analysis of protein expression
levels of iNOS in cell lysates from control and activated microglia with LPS stimulation (Mean ± SD, n = 5). b, c Components of the inflammasome,
NLRP3 and pro-Caspase 1, were measured by western blot in cell lysates with representative pictures of blots (Mean ± SD, n = 5). d Representative
TEM imaging of extracellular vesicle populations from CTRL and LPS-derived microglia. The imaging illustrates heterogeneity and sphere structure
of extracellular vesicles. Typical microvesicles are pointed with red arrows. Scale bars: 500 nm. e Western blots showed alterations of expression levels
of vesicle markers indicated different origins of extracellular vesicles from CTRL and LPS. Three biological independent samples were blotted in each
condition. f The size of extracellular vesicles was determined in diameter from CTRL and LPS-treated microglia. The mean size shows the average
diameter of extracellular vesicles in samples (n = 12). D90 demonstrates the upper limit of extracellular vesicles size in 90% of the population (n = 12).
g Representative histograms of extracellular vesicles size distributions collected from CTRL and LPS conditions. Sample from LPS condition was diluted
25 times more than control to obtain similar concentration of EVs to demonstrate size distribution. Concentrations (× 106 particles/ml) by size (nm) of
recorded extracellular vesicles are showed. The major subpopulations in EV samples are indicated with digitals showing the mean diameter of extracellular
vesicles. Histograms were generated from five independent measurements by NTA 2.2 software (Unpaired t test, *P< 0.05; ***P< 0.001; ****P< 0.0001)
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TNF inhibition. Interestingly, the reduction of EVs re-
leased upon TNF inhibition was reduced 16-fold, sug-
gesting that TNF signaling is particularly important
when it comes to reducing the number of EV released in
proinflammatory activation of microglia (Fig. 3a). To-
gether, these results implicate that the secretion of EVs
is dramatically impeded by TNF inhibition in
LPS-activated microglia, which is only partly associated
to an overall reduction in the inflammatory status.
Evaluation of systemic inflammation in mice after focal
cerebral ischemia
As the level of TNF has shown to be upregulated in EVs
under LPS activation in vitro, we next studied whether
the secretion of EVs in vivo was affected by complete ab-
lation of TNF signaling in a strong neuroinflammatory
situation. To this purpose, we chose an experimental
stroke model, permanent middle cerebral artery occlu-
sion (pMCAO), as an in vivo inflammatory model. Ex-
perimental stroke in rat and mouse is known to induce
neuroinflammation in the brain [26, 27] as well as alter
the inflammatory response in the periphery [28, 29]. Our
earlier study has revealed significant increase of TNF re-
ceptors, toll-like receptor (TLR) 2 and IL-1β at mRNA
levels in wild type (WT) and TNF-KO mice 1 day after
pMCAO, indicating inflammation occurred in the brain
[18]. We also wanted to assess systemic inflammatory
response in mice after pMCAO. Therefore, we measured
levels of different cytokines in serum using Multiplex
ELISA from WT and TNF-KO mice without manipula-
tion and 1 day after pMCAO. TNF expression levels
were statistically elevated in WT at day 1 and unchanged
in TNF-KO mice (Additional file 4). IL-5 and IL-12p70
were also found statistically elevated in WT mice 1 day
after manipulation, but not in TNF-KO (Fig. 4a, c).
While in the case of IL-1β, IL-6, and KC/GRO, expres-
sion levels were considerably increased 1 day after
pMCAO in both types of mice compared with unmanip-
ulated mice (Fig. 4b, d, f ). Notably, such increases in-
duced by pMCAO were significantly attenuated by
deficiency of TNF in mice. Levels of IL-10 were remark-
ably lower in TNF-KO mice compared with WT mice
after pMCAO, but not before (Fig. 4e). Levels of IL2,
IL-4, and IFNγ were remained at baseline levels at day 1
in both types of mice subjected to pMCAO (Additional
file 4). In conclusion, we found clear evidence of signifi-
cant upregulation of proinflammatory cytokines at day 1
after pMCAO in both types of mice. However, in
TNF-KO mice, such inflammation induced by pMCAO
was remarkably attenuated at day 1 after stroke.
Decreased EVs in TNF knockout mice after focal cerebral
ischemia
Given the impact of pMCAO on systemic inflammation
in WT and TNF-KO mice, we examined microglia acti-
vation in the brain. We observed that TNF co-localized
with the microglial marker, CD11b, in the peri-infarct
area 1 day after pMCAO (Fig. 3d), which shows that
focal cerebral ischemia could induce an initial phase of
microglia activation involving TNF signaling and tissue
injury, as we have shown before [30]. Moreover, the vol-
ume of infarct was also assessed in WT mice and
TNF-KO mice 5 days after pMCAO in the previous
study, which has shown that the injury was significantly
larger in TNF-KO mice than WT mice [18]. Previously,
we have shown that the infarct volume correlates with
the number of EVs in plasma after this stroke model
[31]. Thus, we analyzed the number of EVs in the
plasma of TNF-KO mice after pMCAO. The production
of EVs increased from both genotypes 5 days after
pMCAO indicating inflammation occurred, which in line
with our previous findings in vitro (Fig. 3a, c). Import-
antly, we found here that a complete ablation of TNF
successfully reduced the counts of EVs in the plasma of
TNF-KO mice 5 days after induction of permanent focal
cerebral ischemia (Fig. 3c), but not at day 1 (Add-
itional file 5). These results are consistent with our in
vitro data and indicate the number of EVs is related to
an inflammatory event and that TNF signaling is import-
ant in the mechanism regulating EV release.
Identification of microglial EVs proteins
To further elucidate cellular communication by EVs
under inflammation, we set out to identify proteins in
association to EVs released by BV2 cells. To this aim,
Fig. 2 Increased levels of proinflammatroy cytokines in microglia-
derived extracellular vesicles upon LPS activation. The levels of
cytokines were analyzed by multiplex ELISA plate. a Bar graph shows
a significant upregulation of TNF (n = 3). b Bar graph shows a
significant upregulation of IL-6 (n = 6)(Mean ± SD, Unpaired t test,
*P < 0.05; ***P < 0.001)
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proteomic analysis was performed using mass spectrom-
etry on EV samples from LPS-activated and control
microglia. Biological independent duplicates of EVs were
pooled together and analyzed. In total, 86 proteins were
identified with two peptides confirmed and high confi-
dence, as -10lgP is set for 20 as threshold, using PEAKS
analysis program (Tables 1 and 2) [32]. In total, 37 pro-
teins from control and 58 proteins from LPS-stimulated
microglia were successfully mapped with UniProt data-
base. Among them, we found 9 proteins in common
(Table 3) and 49 specific proteins present in LPS condi-
tion. The analysis showed enzymes, chaperones, ribosomal
structure proteins, and membrane receptors previously re-
ported in other immune cells in our samples (Fig. 5 d, e).
Of these, the majority of the identified proteins were asso-
ciated with RNA binding, and more than half of them had
Gene Ontology annotations related to membrane and
extracellular exosome (Fig. 5c, d). The identified proteins
were also compared with the ExoCarta database, which
has exosomal proteins identified from previous publica-
tions [21]. In our samples, only one protein has not been
reported in ExoCarta database (Fig. 5a). Compared with
top 100-ranked proteins presented in the database, we
identified 17 of them in our study (Fig. 5a). Notably, 89.5%
proteins from this study have not been reported before
and first identified in microglia (Table 4), suggesting that
these cells are releasing specific EVs.
Functional profiles of the quantified microglia EVs proteins
Next, we wanted to know the functions of the quantified
proteins differentially secreted in EVs under LPS activa-
tion. The 86 quantified proteins in the microglial-derived
Fig. 3 Reduction in the number of microglia-derived extracellular vesicles by inhibition of TNF signaling pathway. Extracellular vesicles were visualized
by TEM. Concentrations of extracellular vesicles in conditional media and plasma from mice were measure by NTA. a Comparison of extracellular
vesicles concentrations in different conditional media. BV2 microglia cell line was treated with either LPS (1 μg/ml) or etanercept (200 ng/ml) or in the
presence of both. Control (CTRL) was cells without any treatment (Mean ± SD, one-way ANOVA, ***P < 0.001, n = 3). b Expression levels of iNOS in BV2
cells previously treated with different conditions were analyzed by western blot. iNOS bands were not able to be visualized in the conditions of
control and etanercept due to out of the detection limit (Mean ± SD, Unpaired t-test, *P < 0.05, n = 4). c Bar graph shows a comparison of the amount
of extracellular vesicles in plasma from mice (WT, n = 6; TNF-KO, n = 6) without surgery and mice (WT, n = 9; TNF-KO, n = 8) 5 days after a stroke model,
permanent middle cerebral artery occlusion (pMCAO) (Mean ± SD, one-way ANOVA followed by Tukey’s test for multiple comparisons, *P < 0.05,
***P < 0.001). d The brain section in area of infarct from C57BL/6 mouse subjected to pMCAO stained with anti-TNF (green) and anti-CD11b (red),
nuclei stained with DAPI. TNF+ cells are also stained for CD11b indicated with arrow; scale bar: 20 μm
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EVs were analyzed using FunRich software [21] to validate
our data referred to the Vesiclepedia Exosome Database
[33]. The analysis was based on their cellular compart-
ments to which they belong, their molecular function and
the biological process in which they are involved. In the
analysis, some of the proteins were annotated in more
than one cellular component, molecular function, and bio-
logical process.
Firstly, enrichment in pathways from membrane and
extracellular exosome was observed for GO analysis on
cellular component (Fig. 5d). There were large increases
in proteins from LPS-stimulated EVs from ribosome, focal
adhesion, extracellular matrix, and membrane (Fig. 5d). In
contrast, a reduction of proteins associated with extracel-
lular exosome was found in LPS-stimulated EVs, which is
also confirmed by western blot with increased ratio of
flotillin-1 and CD63 indicating more MVs released. In the
categories of molecular function, the majority of the pro-
teins were annotated to RNA binding, 38.9% in control
and 72.4% in LPS (Fig. 5c). Importantly, the proteins con-
tributed to ribosome function raised from 2.8 to 56.9%
after LPS challenge (Fig. 5c). The profile of proteins in
molecular function was dramatically altered after inflam-
matory stimulation. It is likely that microglia released a
distinct population of EVs related to transduction and
translation after activation of LPS. Intriguingly, the profile
of EVs was peculiarly different after activation according
to classification of biological process (Fig. 5e). EVs were
found involved in regulation of neuron projection devel-
opment at “rest” status (control), however, with activation
the proteins identified in EVs shifted to ribosomal assem-
bly and translation. The role of microglia was changed
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Fig. 4 Systemic inflammation in mice after focal cerebral ischemia. The levels of cytokines in serum were analyzed by multiplex ELISA from WT
and TNF-KO mice without manipulation and 1 day after focal cerebral ischemia. a and c Bar graphs show significant upregulation of IL-5 and IL-
12p70 in WT mice after pMCAO. b, d, f Bar graphs show significant upregulation of IL-1β, IL-6, and KC/GRO in both types of mice subjected to
pMCAO. e Bar graph shows remarkable reduction of IL-10 in TNF-KO mice compared with WT mice 1 day after pMCAO. (Mean ± SD, one-way
ANOVA followed by Tukey’s test for multiple comparisons, n = 3–6, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001)
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from “rest” state to “activated” state by not only produc-
tion of cytokine and chemokine, but also with altered se-
cretion of EVs, which could be directly linked to
detrimental inflammatory responses related to neurode-
generative diseases.
In larger proportion, 49 proteins were exclusively
present in EVs samples from LPS activation, including
some cytoskeleton proteins and ribosomal proteins. Im-
portantly, three of them were associated with inflamma-
tory and neuropathological pathways: tubulin beta 4B
Table 1 List of proteins identified in control EV samples
Protein ID Gene name Protein name Score
P08226 APOE Apolipoprotein E 506
P21956 MFGE8 Lactadherin 136
P21460 CST3 Cystatin-C 123
Q9WU78 PDCD6IP Programmed cell death 6-interacting protein 121
P11152 LPL Lipoprotein lipase 107
Q8VDN2 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 105
P62737 ACTA2 Actin, aortic smooth muscle 84
Q61753 PHGDH D-3-phosphoglycerate dehydrogenase 80
P07901 HSP90AA1 Heat shock protein HSP 90-alpha 80
P10605 CTSB Cathepsin B 75
P01942 HBA Hemoglobin subunit alpha 73
P63017 HSPA8 Heat shock protein 8 71
Q62419 SH3GL1 Endophilin-A2 70
Q8R366 IGSF8 Immunoglobulin superfamily member 8 69
Q68FD5 CLTC Clathrin heavy chain 1 67
P10923 SPP1 Osteopontin 64
Q61207 PSAP Prosaposin 64
P06869 PLAU Urokinase-type plasminogen activator 62
Q8CGP5 HIST1H2AF Histone H2A type 1-F 61
P52480 PKM Pyruvate kinase 59
P17182 ENO1 Alpha-enolase 56
P04104 KRT1 Keratin, type II cytoskeletal 1 50
P68369 TUBA1A Tubulin alpha-1A chain 47
P01887 B2M Beta-2-microglobulin 45
P09405 NCL Nucleolin 44
P09055 ITGB1 Integrin beta-1 42
P01901 H2-K1 H-2 class I histocompatibility antigen, K-B alpha chain 41
P01899 H2-D1 H-2 class I histocompatibility antigen, D-B alpha chain 36
P29341 PABPC1 Polyadenylate-binding protein 1 41
P06797 CTSL Cathepsin L1 38
P10852 SLC3A2 4F2 cell-surface antigen heavy chain 37
P08905 LYZ2 Lysozyme C-2 34
P10126 EEF1A1 Elongation factor 1-alpha 1 28
Q61937 NPM1 Nucleophosmin 27
Q9DBJ1 PGAM1 Phosphoglycerate mutase 1 25
P28798 GRN Granulins 24
P14206 RPSA 40S ribosomal protein SA 24
Proteins retrieved in control extracellular vesicle samples from mass spectrometry. Protein ID and gene name are according to Uniprot Knowledgebase. Score
values were obtained using MASCOT. The Score shows how well the observed protein matches to the stated protein in the database. Only protein identifications
supported by at least two high confident peptides (confidence > 95%) were considered
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Table 2 List of proteins identified in LPS EV samples
Protein ID Gene name Protein name Score
P68372 TUBB4B Tubulin beta-4B chain 258
P62242 RPS8 40S ribosomal protein S8 201
P47963 RPL13 60S ribosomal protein L13 181
Q9CZX8 RPS19 40S ribosomal protein S19 178
P15864 HIST1H1C Histone H1.2 172
Q8VEK3 HNRNPU Heterogeneous nuclear ribonucleoprotein U 148
Q9CR57 RPL14 60S ribosomal protein L14 146
P63276 RPS17 40S ribosomal protein S17 138
P11152 LPL Lipoprotein lipase 130
P16858 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 128
P68369 TUBA1A Tubulin alpha-1A chain 123
P62082 RPS7 40S ribosomal protein S7 106
Q9D8E6 RPL4 60S ribosomal protein L4 101
P35979 RPL12 60S ribosomal protein L12 101
P14131 RPS16 40S ribosomal protein S16 100
P70696 HIST1H2BA Histone H2B type 1-A 100
P12970 RPL7A 60S ribosomal protein L7a 98
P60710 ACTB Actin, cytoplasmic 1 94
Q9CXW4 RPL11 60S ribosomal protein L11 85
Q9CZM2 RPL15 60S ribosomal protein L15 84
P02301 H3F3C Histone H3.3C 83
P47911 RPL6 60S ribosomal protein L6 83
P43276 HIST1H1B Histone H1.5 83
Q8CGP5 HIST1H2AF Histone H2A type 1-F 82
P14115 RPL27A 60S ribosomal protein L27a 74
P27659 RPL3 60S ribosomal protein L3 72
O55142 RPL35A 60S ribosomal protein L35a 70
P25206 MCM3 DNA replication licensing factor MCM3 68
P62702 RPS4X 40S ribosomal protein S4, X isoform 63
P10126 EEF1A1 Elongation factor 1-alpha 1 63
Q8BP67 RPL24 60S ribosomal protein L24 62
P14206 RPSA 40S ribosomal protein SA 62
P11499 HSP90AB1 Heat shock protein HSP 90-beta 60
P08226 APOE Apolipoprotein E 60
P35980 RPL18 60S ribosomal protein L18 59
P63017 HSPA8 Heat shock protein 8 59
P80318 CCT3 T-complex protein 1 subunit gamma 58
P62918 RPL8 60S ribosomal protein L8 57
O08585 CLTA Clathrin light chain A 55
Q9Z1Q9 VARS Valine-tRNA ligase 54
P01942 HBA Hemoglobin subunit alpha 51
P97351 RPS3A 40S ribosomal protein S3a 50
P62806 HIST1H4A Histone H4 48
P62270 RPS18 40S ribosomal protein S18 44
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(TUBB4B), heterogeneous nuclear ribonucleoprotein U
(HNRNPU) and serum amyloid A 3 (SAA3). Nine pro-
teins were shared in samples from control and LPS con-
ditions (Fig. 5b). Proteins related to immune system
process and stimuli response were detected in both sam-
ples: lipoprotein lipase (LPL), apolipoprotein E (APOE),
and heat shock protein 8 (HSPA8). Notably, APOE was
particular with high score in the EVs before and after
LPS activation. Variants of APOE (APOE4) is known as
the strongest risk factor for late onset Alzheimer’s dis-
ease [34] and has also been suggested to have a proin-
flammatory effect on microglia [35].
Discussion
Compelling evidence has suggested that the activation of
innate immunity and neuroinflammation play crucial
roles in neurodegenerative diseases [36–38]. Microglia
are an essential component in innate immunity in the
CNS. Activation of microglia is followed by the initiation
of intracellular machinery that leads to production of
cytotoxic and proinflammatory cytokines and chemo-
kines, which promote progression of inflammation and
affect neighboring cells through different mechanisms.
The secretion of proinflammatory signals can be con-
ducted in classic secretion manner or non-canonical
manner via vesicles. Previous studies have shown the im-
portant role of EVs in regulation of cytokine production
on recipient cells and propagation of pathogenic pro-
teins [11, 39].
The functions of microglia in the brain are diverse
depending on stimulus and different brain regions. In
response to different inflammatory/homeostatic condi-
tions, they can be either beneficial or detrimental.
Increasing evidence has suggested that there is a spectrum
of activation in microglia based on the profile of secreted
molecules [3]. However, the importance of EV released by
microglia has not been well characterized. Thus, in the
present study, we directly evaluated effects of
LPS-stimulation on EVs derived from BV2 microglia, in
terms of physical and biological properties. Our results
demonstrate that (i) upon LPS-activation, the size dis-
tribution of EVs released from microglia increases in
size, indicating larger vesicles are released under in-
flammatory conditions; (ii) IL-6 and in particular TNF
are increasingly secreted in microglia-derived EVs after
LPS challenge; (iii) inhibiting the TNF signaling path-
way resulted in a robust reduction in the number of
vesicles released from LPS-treated microglia and in
Table 2 List of proteins identified in LPS EV samples (Continued)
Protein ID Gene name Protein name Score
P62911 RPL32 60S ribosomal protein L32 43
P14869 RPLP0 60S acidic ribosomal protein P0 41
Q9JIK5 DDX21 Nucleolar RNA helicase 2 41
P62281 RPS11 40S ribosomal protein S11 41
Q68FD5 CLTC Clathrin heavy chain 1 40
P62717 RPL18A 60S ribosomal protein L18a 39
P86048 RPL10L 60S ribosomal protein L10-like 39
P62267 RPS23 40S ribosomal protein S23 37
P25444 RPS2 40S ribosomal protein S2 36
P14148 RPL7 60S ribosomal protein L7 31
P53026 RPL10A 60S ribosomal protein L10a 28
P62264 RPS14 40S ribosomal protein S14 28
P62908 RPS3 40S ribosomal protein S3 23
P04918 SAA3 Serum amyloid A-3 protein 23
Proteins retrieved in LPS extracellular vesicles samples from mass spectrometry. Protein ID and gene name are according to Uniprot Knowledgebase. Score values
were obtained using MASCOT. The score shows how well the observed protein matches to the stated protein in the database. Only protein identifications
supported by at least two high confident peptides (confidence > 95%) were considered
Table 3 The common proteins shared in CTRL and LPS EV
samples
Protein ID Gene name Protein name
P08226 APOE Apolipoprotein E
P11152 LPL Lipoprotein lipase
P01942 HBA Hemoglobin subunit alpha
P63017 HSPA8 Heat shock protein 8
Q68FD5 CLTC Clathrin heavy chain 1
Q8CGP5 HIST1H2AF Histone H2A type 1-F
P68369 TUBA1A Tubulin alpha-1A chain
P10126 EEF1A1 Elongation factor 1-alpha 1
P14206 RPSA 40S ribosomal protein SA
Proteins retrieved in extracellular vesicle samples from mass spectrometry.
Protein ID and gene name are according to Uniprot Knowledgebase
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Fig. 5 Bioinformatic analysis of the identified proteins in BV2 microglia-derived extracellular vesicles. Gene ontology (GO) analysis of the identified
proteins was performed using Exocarta based software FunRich. The comparison was carried on proteins expressed exclusively in each condition.
a Comparison of 86 identified proteins from microglial extracellular vesicles with online database Exocarta and the top 100 proteins commonly
reported in the same database. b Comparison of the number of proteins identified and quantified in control microglia and LPS-activated
microglia derived extracellular vesicles samples. c Bioinformatic analysis from FunRich shows comparison of GO analysis on Molecular Function on
proteins from CTRL and LPS-activated microglia released extracellular vesicles (GO terms are with P < 0.01). d Bioinformatic analysis from FunRich
shows comparison of GO analysis on Cellular Component on proteins from CTRL and LPS-activated microglia released extracellular vesicles (GO
terms are with P < 0.01). e Bioinformatic analysis from FunRich shows comparison of GO analysis on Biological Process on proteins from CTRL and
LPS-activated microglia released extracellular vesicles (GO terms are with P < 0.01)
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Table 4 New proteins found in present microglia-derived EV samples
Protein ID Gene name Protein name
P08226 APOE Apolipoprotein E
P21460 CST3 Cystatin-C
Q8VDN2 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1
P62737 ACTA2 Actin, aortic smooth muscle
Q61753 PHGDH D-3-phosphoglycerate dehydrogenase
P10605 CTSB Cathepsin B
P01942 HBA Hemoglobin subunit alpha
Q62419 SH3GL1 Endophilin-A2
Q8R366 IGSF8 Immunoglobulin superfamily member 8
Q68FD5 CLTC Clathrin heavy chain 1
P10923 SPP1 Osteopontin
Q61207 PSAP Prosaposin
P06869 PLAU Urokinase-type plasminogen activator
Q8CGP5 HIST1H2AF Histone H2A type 1-F
P04104 KRT1 Keratin, type II cytoskeletal 1
P68369 TUBA1A Tubulin alpha-1A chain
P01887 B2M Beta-2-microglobulin
P09405 NCL Nucleolin
P09055 ITGB1 Integrin beta-1
P01901 H2-K1 H-2 class I histocompatibility antigen, K-B alpha chain
P01899 H2-D1 H-2 class I histocompatibility antigen, D-B alpha chain
P29341 PABPC1 Polyadenylate-binding protein 1
P06797 CTSL Cathepsin L1
P10852 SLC3A2 4F2 cell-surface antigen heavy chain
P08905 LYZ2 Lysozyme C-2
P10126 EEF1A1 Elongation factor 1-alpha 1
Q61937 NPM1 Nucleophosmin
P28798 GRN Granulins
P14206 RPSA 40S ribosomal protein SA
P68372 TUBB4B Tubulin beta-4B chain
P62242 RPS8 40S ribosomal protein S8
P47963 RPL13 60S ribosomal protein L13
Q9CZX8 RPS19 40S ribosomal protein S19
P15864 HIST1H1C Histone H1.2
Q8VEK3 HNRNPU Heterogeneous nuclear ribonucleoprotein U
Q9CR57 RPL14 60S ribosomal protein L14
P63276 RPS17 40S ribosomal protein S17
P62082 RPS7 40S ribosomal protein S7
Q9D8E6 RPL4 60S ribosomal protein L4
P35979 RPL12 60S ribosomal protein L12
P14131 RPS16 40S ribosomal protein S16
P70696 HIST1H2BA Histone H2B type 1-A
P12970 RPL7A 60S ribosomal protein L7a
P60710 ACTB Actin, cytoplasmic 1
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mice subjected to pMCAO; and (iv) in response to LPS,
BV2 microglia release EVs with a distinct proteomic
profile related to transcription and translation.
EVs can either enhance or suppress inflammation and
act as main factors to regulate inflammation and im-
munity [40, 41]. There is evidence showing microglia
can release IL-1β, upon exposure to ATP derived from
astrocytes, by shedding MVs which contain the entire
machinery important for processing of it including the
P2X7 receptors [42]. This is consistent with our findings
that EVs contain more molecules related to transcription
and translation in activated state and include a particular
population of MVs budding from the plasma membrane.
The mechanism underlying release of EV is still not
clear. TNF can induce neurotoxicity by modulating glu-
tamate production that results in excitotoxic neuronal
death [43]. One study conducted by Wang et al. has
shown that TNF promotes the release of EVs from astro-
cytes through increased expression of glutaminase,
which convert glutamine to glutamate [44]. TNF can
also induce extensively production of glutamate from
microglia in an autocrine manner to cause excitotoxicity
Table 4 New proteins found in present microglia-derived EV samples (Continued)
Protein ID Gene name Protein name
Q9CXW4 RPL11 60S ribosomal protein L11
Q9CZM2 RPL15 60S ribosomal protein L15
P02301 H3F3C Histone H3.3C
P47911 RPL6 60S ribosomal protein L6
P43276 HIST1H1B Histone H1.5
Q8CGP5 HIST1H2AF Histone H2A type 1-F
P14115 RPL27A 60S ribosomal protein L27a
P27659 RPL3 60S ribosomal protein L3
O55142 RPL35A 60S ribosomal protein L35a
P25206 MCM3 DNA replication licensing factor MCM3
P62702 RPS4X 40S ribosomal protein S4, X isoform
P10126 EEF1A1 Elongation factor 1-alpha 1
Q8BP67 RPL24 60S ribosomal protein L24
P14206 RPSA 40S ribosomal protein SA
P11499 HSP90AB1 Heat shock protein HSP 90-beta
P08226 APOE Apolipoprotein E
P35980 RPL18 60S ribosomal protein L18
P63017 HSPA8 Heat shock protein 8
P80318 CCT3 T-complex protein 1 subunit gamma
P62918 RPL8 60S ribosomal protein L8
P62911 RPL32 60S ribosomal protein L32
P14869 RPLP0 60S acidic ribosomal protein P0
Q9JIK5 DDX21 Nucleolar RNA helicase 2
P62281 RPS11 40S ribosomal protein S11
P62717 RPL18A 60S ribosomal protein L18a
P86048 RPL10L 60S ribosomal protein L10-like
P62267 RPS23 40S ribosomal protein S23
P25444 RPS2 40S ribosomal protein S2
P14148 RPL7 60S ribosomal protein L7
P53026 RPL10A 60S ribosomal protein L10a
P62264 RPS14 40S ribosomal protein S14
P62908 RPS3 40S ribosomal protein S3
P04918 SAA3 Serum amyloid A-3 protein
Proteins identified in present study were compared with proteins uploaded in Exocarta database from microglial origin. Protein ID and gene name are according
to Uniprot Knowledgebase
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and contribute to neuronal damage [45]. Thereby, these
findings together with our results suggest that microglial
EV release could be potentially modulated by TNF
through specifically regulated mechanisms.
Our data suggests that inhibition of TNF signaling in
microglia may impact on inflammation, with an ob-
served reduction both in the release of different cyto-
kines and in the total number of EVs released, implying
that the release of EVs in activated microglia seems to
be regulated. This idea is further supported by data from
our experimental stroke model that showed altered EV
counts in plasma from TNF-KO mice compared to WT.
These results contradict previous work that showed an
increase in the amount of MVs in mice treated with
TNF inhibitor for 5 days after pMCAO compared to
saline-treated mice [31]. It is therefore reasonable to as-
sume that the difference we observed is due to the dif-
ferent experimental set-up. A systemic administration of
TNF inhibitor in the mice 30 min after surgery could
merely have a transient effect on the TNF signaling path-
way, whereas using the TNF-KO model is expected to be
more stable to investigate and characterize long-term ef-
fects of EVs release.
From our previous study, pMCAO could initiate
microglia activation and inflammation in the brain [18,
28]. Therefore, we also evaluated systemic inflammation
in mice subjected to pMCAO. Although several inflam-
matory factors, such as IL-1β and IL-6, were significantly
increased in both types of mice at day 1 after manipula-
tion, such induction was attenuated in TNF-KO mice.
Another study has shown that EVs derived from macro-
phages stimulated with bacterial infection are able to in-
crease secretion of proinflammatory cytokines in
recipient cells, including TNF [17]. Taken together, we
can speculate that inflammatory propagation can be mit-
igated by a reduction in the number of microglia-derived
EVs, thus halting inflammation via TNF signaling. How-
ever, this is complicated by the fact that there are two
forms of TNF, soluble TNF (solTNF), which is related to
neurotoxicity and inflammation, while the transmem-
brane TNF (tmTNF) is involved in functional recovery
and neuroprotection [18, 46]. Hence, both the cellular
contribution to TNF signaling and specifically the form
of TNF carried in microglial EVs is important to evaluate
final outcome of experiment, neuroprotective or neuro-
toxic. In our study, we measured total TNF in EVs in-
cluding tmTNF and solTNF. However, the specific form
of TNF is likely to be important for the inflammatory
and cytoprotective outcome. We believe such studies in-
vestigating the specific form of TNF carried in EVs are
important in future studies.
We also studied the protein composition to further
characterize the EVs released under control or inflamma-
tory conditions. Using western blot analysis, we looked for
changes in the levels of either plasma membrane or endo-
somal markers to elucidate where these vesicles had origi-
nated. Indeed, we observed an increase in signal from
plasma membrane markers when compared to endosomal
markers upon LPS activation. When combined with the
increase in overall size observed with NanoSight, this sup-
ports our theory that more MVs are released under in-
flammatory conditions.
Furthermore, our proteomic analysis indicated that the
two populations of EVs were dramatically different in
categories of molecular function and biological process
under GO analysis. From the qualitative proteomic ana-
lysis, 86 proteins were identified with high accuracy.
Compared to Exocarta database, most of the proteins
have been reported in previous studies in exosomes from
other cell types, where 89.5% of the quantified proteins
were firstly identified in microglial EVs. The small over-
lap with previous studies is most likely due to a lack of
studies utilizing microglia-derived EVs, with a sole study
performed on EVs from the N9 microglial cell line re-
sponsible for all microglial proteins present in ExoCarta
[15]. It was also clear from the FunRich analysis [20]
that the proteins detected in EVs from LPS-treated cells
had different functions to those from control cells, with
proteins involved in RNA binding and structural compo-
nents of the ribosome more prevalent in LPS-derived
EVs. While the analysis on the cellular origin of the EV
proteins revealed that the extracellular exosome and
membrane were dominant from both conditions, it is of
interest to note that EVs isolated from inflammatory
condition were detected with more membrane and less
exosome proteins, consistent with a shift towards MV
release rather than exosome.
For the first time, our data indicates that microglia
change its EVs releasing machinery after LPS activation
with an increase in the overall number of EVs, and more
EVs budding from the membrane. It is tempting to
speculate that non-activated microglia have an expedient
and controlled release of EVs, whereas in an inflamma-
tory condition microglia release a large variation of EVs
that will perturb the normal homeostatic function of
microglia. We also think that, upon LPS-stimulation,
microglia respond to release populations of extracellular
cargoes with a unique proteomic profile related to RNA
transcription and translation. The existence of various
RNA molecules in EVs is well-established including
mRNA and microRNA. In fact, microRNAs can function
as ligands for TLRs and induce immune responses or in-
hibit activation by suppressing TLR signaling [13, 47].
These RNAs are selectively sorted to EVs under different
mechanisms [47]. However, the mechanisms responsible
for this packaging are not clear. Thus, our study implies
proteins potentially involved in such mechanisms that
are increased when inflammation takes place. According
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to our proteomic data, we speculate that EVs could actu-
ally carry the whole machinery not only RNAs to recipi-
ent cells and surrounding tissue.
Finally, by comparing the protein cargoes from
LPS-activated and non-activated BV2 microglia, we were
able to identify potential candidates likely to be involved
in the communication of microglial cells with other ef-
fector cells under inflammation. We found 49 proteins
exclusively present in EVs in the presence of LPS.
Among them, TUBB4B, HNRNPU, and SAA3 are pro-
teins related to inflammation and neuropathology. In-
deed, TUBB4B is a member of tubulin family and known
as a component of cytoskeleton [48]. Liu X et al, sug-
gested that TUBB4B may be a part of the same disease
pathway as leucine-rich repeat kinase 2 (LRRK2), which
is a crucial factor to understand the etiology of Parkin-
son’s disease (PD) [49]. HNRNPU acts as a key factor to
maintain 3D structure of chromatin and has been re-
ported as a posttranscriptional regulator for NF-κB in-
flammatory pathway [50]. In addition, SAA3 is a
member of serum amyloid A (SAA) and acute phase
protein accompanying with other inflammatory cyto-
kines and chemokines [51]. It has been implied to play a
role in the inflammatory processes occurring in Alzhei-
mer’s disease (AD) and multiple sclerosis (MS) [51]. In
addition to those proteins found exclusively in LPS EVs,
we identified APOE in EVs from both LPS and control
conditions. This protein is commonly present in mem-
branes and is considered one of the most important li-
poproteins involved in cholesterol shuttling between
astrocytes and neurons along with being involved in re-
modeling and reorganization of neuronal networks after
injury [34]. It is also one of the major genetic risk factors
for late onset sporadic AD and can function as a ligand
in receptor-mediated endocytosis with extracellular
β-amyloid [34, 52].
Conclusions
The present data show that upon activation by LPS, BV2
microglia release EVs with a distinct proteomic profile
compared to control. Our data suggests that under these
inflammatory conditions, MVs are the predominate EV,
containing increased levels of TNF in particular, and to a
lesser degree IL-6. We further provide evidence in vitro
and in vivo that TNF signaling is important in quantita-
tively controlling EV release. Furthermore, through
proteomic analysis, we are able to provide lists of pro-
teins with the potential to modulate EV trafficking in
microglia, in particular a change in EV proteins related
to neuronal maintenance and protein translation after
LPS activation. We believe that EV regulation in micro-
glia and its specific role in neuroinflammation will be
important to fully understand the inflammatory patho-
genesis in neurodegenerative diseases.
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